Research Progress of Fluorescent Probe Imaging Technology in the Diagnosis and Treatment of Breast Cancer

Haihui Gong

doi:10.54097/h7hnc415

Authors

Haihui Gong

DOI:

https://doi.org/10.54097/h7hnc415

Keywords:

Fluorescence Imaging, Probe, Breast Cancer, Diagnosis, Imaging

Abstract

As the most common malignant tumor among women worldwide, breast cancer requires early and accurate diagnosis, metastasis monitoring, and effective treatment to improve patient prognosis. Current diagnostic approaches mainly include imaging examinations (e.g., ultrasound, magnetic resonance imaging (MRI), and mammography) as well as pathological examination, all of which have certain limitations. Thus, it is crucial to continuously explore novel, rapid, accurate, and minimally invasive diagnostic methods for breast cancer. Fluorescent probe imaging technology has garnered extensive attention in medical research due to its advantages of high tissue penetration, high sensitivity, non-invasiveness, and real-time visualization. Nanostructured probes, which possess excellent biocompatibility and remarkable physicochemical properties (including superior optical performance), have been extensively studied and reported in the field of breast cancer diagnosis, demonstrating broad application prospects.

Downloads

Download data is not yet available.

References

[1] Hu ZZ. LyP-1-modified gold@cerium oxide nanoprobe for imaging and synergistic therapy of triple-negative breast cancer [D]. Jilin University; 2025. In Chinese.

[2] Pires ICB, Shuchi SI, Tostes BVA, et al. Theranostics using MCM-41-based mesoporous silica nanoparticles: integrating magnetic resonance imaging and novel chemotherapy for breast cancer treatment. Int J Mol Sci. 2024;25(15).

[3] Shen HY, Yan ZX, Li L, et al. Research progress of fluorescent probes in near-infrared fluorescence imaging. Zhejiang Med J. 2026;48(1):98-101. In Chinese.

[4] Mantashlou MJ, Alizadeh E, Moghaddam SV, et al. Development of AS1411 aptamer-conjugated chitosan-carbon dot nanocarriers for targeted drug delivery and fluorescent imaging in breast cancer therapy. J Biol Eng. 2026.

[5] Lou KL, Bai JW, Liu HT, et al. TROP2-targeted NIR-II fluorescence imaging for visualizing surgical margins and metastatic sentinel lymph nodes in breast cancers. Proc Natl Acad Sci U S A. 2026;123(8):e2519420123.

[6] Li J, Zhao R, Zhang J, et al. PET/NIR-II fluorescence imaging and image-guided surgery of breast cancer using a CD47-specific nanobody. View. 2025;6(6).

[7] Zhang Y, Zheng X, Huang Y, et al. EDB-FN-targeted probes for near infrared fluorescent imaging and positron emission tomography imaging of breast cancer in mice. Sci Rep. 2024;14(1):22056.

[8] Cai W, Ge J, Dong J, et al. A viscosity-activable nano-micelle with aggregation-induced emission for boosting NIR-II fluorescence imaging-guided synergetic photodynamic/ photothermal therapy of breast cancer. Mater Today Bio. 2025;35:102302.

[9] Yan X, Sun Y, Tan Y, et al. A water-soluble aggregation-induced emission luminogen for NIR-I/NIR-II fluorescence imaging of breast cancer bone metastases. Biosens Bioelectron. 2025;268:116903.

[10] Guo X, Gao XM, Yao Y. Computer-aided design of novel HER2-targeted cyclic peptide PET probes and imaging evaluation for breast cancer. J Oncol Imaging. 2025;34(6):643-654. In Chinese.

[11] Zhang H. Probe set and method for detection of circulating tumor nucleic acids in breast cancer based on DNA walker and branched hybridization chain reaction [M]. In Chinese.

[12] Wang M, Shen XJ, Liu J, et al. Probe-based label-free surface-enhanced Raman spectroscopy (SERS) for serum metabolic profiling in breast cancer patients. J Basic Med Clin. 2025;45(5):651-657. In Chinese.

[13] Zhang C, Xu Z, Wu W, et al. Precision delineation of surgical margins across breast cancer subtypes with a novel KIAA1363-targeted NIR fluorescent probe. ACS Sens. 2026.

[14] Teng X, Wang M, Yang H, et al. A novel triphenylamine-based aggregation-induced emission (AIE) probe for breast cancer imaging in vitro and in vivo. Spectrochim Acta A Mol Biomol Spectrosc. 2026;354:127638.

[15] Wan X, Wang S, Ma P, et al. A nitroreductase-triggered NIR fluorescent probe for selective visualization in orthotopic breast cancer. Spectrochim Acta A Mol Biomol Spectrosc. 2026;353:127568.

[16] Chen J, Liu T, Chen Y, et al. Mitochondria-targeting near-infrared fluorescent probe for selective detection and imaging of endogenous/exogenous H₂S in breast cancer models. Chem Commun (Camb). 2025;61(95):18822-18825.

[17] Edil BH Jr, Agarwal H, Panneerselvam M, et al. Monitoring triple-negative breast cancer with a Trop2-targeted peptide PET probe. Radiol Imaging Cancer. 2025;7(6):e259035.

[18] Gao YY, Lou KL, Lin LL, et al. A NIR-II fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer. Cancer Lett. 2026;646: 218429.

[19] Li J, Zhao C, Ma M, et al. In vivo imaging and chemotherapy monitoring of breast cancer with β-galactosidase-activated fluorescence probe. Sens Actuators B Chem. 2025;444 (P2):138418.

[20] Cheng L. Photothermal/ferroptosis synergistic immunotherapy for triple-negative breast cancer based on light-responsive targeted nanoparticles [D]. Chongqing Medical University; 2024. In Chinese.

[21] Lan S, Wang Y, Zhang S, et al. NIR-II fluorescence imaging-guided combinatorial therapy of breast cancer using ICG/chelerythrine-loaded aptamer-targeted liposomes. ACS Appl Bio Mater. 2025;8(7):6350-6359.

[22] Ning J, Hu G, Wu T, et al. Dual biomarkers-activatable hollow MnO₂-based theranostic nanoplatform for efficient breast cancer-specific multisite fluorescence imaging and synergistic therapy. Anal Chim Acta. 2024;1303:342521.

[23] Qin HY, Gao YJ, Cui T, et al. Application of novel multifunctional nanoprobes modified with cancer cell membrane in breast cancer. J Mol Imaging. 2025;48(5):529-534. In Chinese.

[24] Wang P, Li Y, He Z, et al. Succinylated D-type neuropeptide integrated with iron-based probes for regulating mitochondrial function and homeostasis in breast cancer. J Am Chem Soc. 2026;148(9):9951-9967.

[25] Kułaga D, Strzykalska-Augustyniak A, Gos M, et al. Synthesis and biological evaluation of 1,3,5-triazine and 2-aminopyrimidine scaffolds as chemical probes targeting the 5-HT₇-FOXM1 axis in triple-negative breast cancer. Eur J Med Chem. 2026;309:118776.

[26] Wang P, Wang J, Chen NW, et al. A novel near-infrared fluoro-photoacoustic probe for NIR/PA dual-model imaging and photothermal therapy in breast cancer. Thermochim Acta. 2025;754:180168.

[27] Wang JY, Deng JL, Zhu Y, et al. Novel pH-responsive manganese-based nanoprobe for ferroptosis and magnetic resonance imaging of breast cancer. J Shanghai Jiaotong Univ Med Sci. 2025;45(9):1183-1193. In Chinese.

[28] Liu R, Tan Y, Jiang Y, et al. DNA damage-driven cGAS-STING activation via a nuclear-targeted probe enables potent near-infrared theranostics in breast cancer. Acta Biomater. 2026;213:635-651.

[29] Huang Y, Liang J, Lu W, et al. Diagnostic and therapeutic integration prodrug: dynamic probe engineering via Cys/GSH depletion to amplify type I photodynamic therapy for breast cancer. Anal Chem. 2025;97(31):17175-17183.

[30] Huang YQ, Fan W. VEGFR2-targeted theranostic probe system ⁶⁴Cu/¹⁷⁷Lu-DOTA-diZD for triple-negative breast cancer. J Oncol Imaging. 2025;34(5):461-469. In Chinese.

[31] Carlos OE, Maria P, Miriam C, et al. Axillary reverse mapping using indocyanine green in breast cancer: standardization of the technique. Clin Breast Cancer. 2025;25(3):268-276.

[32] Pop CF, Veys I, Bormans A, et al. Fluorescence imaging for real-time detection of breast cancer tumors using IV injection of indocyanine green with non-conventional imaging: a systematic review of preclinical and clinical studies of perioperative imaging technologies. Breast Cancer Res Treat. 2024;204(3):429-442.

[33] Zhang L, Huai RP, Su YB. Spray-mediated activatable near-infrared ONOO⁻ probe provides near-instant precise guidance for liver and breast cancer resections. Sens Actuators B Chem. 2025;444(P2):138464.

[34] Meng F, Lyu Q, Zhu W, et al. Intraoperative pathological diagnosis for breast cancer with a polarity fluorescent probe targeting lipid droplets. Sens Actuators B Chem. 2025; 443:138305.

[35] Li MF. Dual-probe near-infrared-II fluorescence imaging of sentinel lymph nodes in breast cancer [D]. Jilin University; 2023. In Chinese.

[36] Yang ZH, Yang ZC, Zhao JT, et al. Triple-synergistic mitochondria-targeted NIR fluorescent probe for mitochondrial hydrogen sulfide: precision monitoring and image-guided resection of metastatic breast cancer. Anal Chem. 2025;97(40):22318-22329.

[37] Yuan W, Li S, Hu J, et al. Progress in the application of fluorescent probes for surgical navigation in breast cancer models. ACS Omega. 2025;10(30):32637-32650.